[Graves' disease and bone metabolism].
Thyroid hormone stimulates osteoclastic bone resorption, through increased expression of receptor activator of nuclear factor kappa B ligand (RANKL) in osteoblasts as well as via non-RANKL-mediated pathway. Therefore, in hyperthyroid patients with Graves' disease, bone resorption (urinary excretion of calcium, phosphate, deoxypyridinoline, N-terminal telopeptide of collagen type I) is increased. Due to accelerated bone remodeling, bone formation is also increased. However, the amount of bone formation is less than that of bone resorption, leading to a gradual decrease in bone mineral density (BMD). In young patients, the decreased BMD is reversible, but not in post-menopausal women. Therefore, in these patients with rapid bone looser, bisphosphonates may be beneficial treatment for prevention of osteoporosis and will prevent bone fractures in senile period.
Sato
Kanji
K
Institute of Clinical Endocrinology, Tokyo Women's Medical University.
D000469:Alkaline Phosphatase / Q000378:metabolism; D015519:Bone Density; D016723:Bone Remodeling; D001862:Bone Resorption / Q000209:etiology*; D001842:Bone and Bones / Q000378:metabolism; D004164:Diphosphonates / Q000627:therapeutic use; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006111:Graves Disease / Q000150:complications* / Q000378:metabolism; D006801:Humans; D010006:Osteoblasts / Q000378:metabolism; D010012:Osteogenesis; D010024:Osteoporosis / Q000209:etiology / Q000517:prevention & control; D053244:Osteoprotegerin / Q000378:metabolism; D053245:RANK Ligand / Q000378:metabolism; D011988:Receptors, Thyroid Hormone / Q000378:metabolism
D004164:Diphosphonates; D053244:Osteoprotegerin; D053245:RANK Ligand; D011988:Receptors, Thyroid Hormone; D000469:Alkaline Phosphatase